Oncology News

The FDA approved ramucirumab as single-agent therapy for certain patients with hepatocellular carcinoma.

The FDA granted both orphan drug designation and fast track status to Namodenoson, an advanced liver cancer therapy candidate from Can-Fite BioPharma, according to a press release.

Tiziana Life Sciences announced that treatment with milciclib for advanced hepatocellular carcinoma did not correlate with unexpected signs or signals of toxicity based on results from an interim safety review, according to a press release.

Researchers found that the increased rates of liver cancer-related mortality in the United States were significantly linked to individuals with less education, especially among men.

Patients with hepatocellular carcinoma who had a potential live donor at listing for liver transplantation had a significantly lower risk for mortality compared with those who waited for a deceased donor graft, according to recently published data.

A recent analysis showed that mortality from intrahepatic cholangiocarcinoma has increased globally while mortality from extrahepatic cholangiocarcinoma has leveled off or decreased.

Can-Fite BioPharma announced that the phase 2 study of their advanced liver cancer candidate, Namodenoson, did not achieve its primary endpoint of overall survival, according to a press release.

Many chronic liver complications such as autoimmune hepatitis and nonalcoholic fatty liver disease do not have approved therapies for direct treatment, but the current hepatology pipeline includes several candidates that have recently demonstrated safety in early trials and some that met top-line phase 3 results.

SFA Therapeutics received second patent approval for its liver disease therapy SFA001, according to a press release.

According to a study published in Hepatology, small dense LDL cholesterol independently predicted cardiovascular disease events among liver transplant recipients, according to a study published in Hepatology.